Extended-release formulations of tramadol in the treatment of chronic pain

Bibliography

• Claxon A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-301
   PubMedGoogle Scholar
• Richter A, Anton S, Koch P, Dennett S. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35
   PubMed Web of Science ®Google Scholar
• Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Athritis Rheum 2000;43:1905-15
   PubMed Web of Science ®Google Scholar
• Mongin G. Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother 2007;7:1775-84
   PubMedGoogle Scholar
• Zehr L. Cipher gets U.S. patent for tramadol. 2010. Available from: http://biotuesday.ca/2010/10/07/cipher-gets-u-s-patent-for-tramadol/. [Last accessed 17 January 2010]
   Google Scholar
• Zhang W, Doherty M, Leeb B, EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-88
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Arden N, EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for Inerantional Clinical Studies including Therapuetics (ESCISIT). Ann Rheum Dis 2005;64:669-81
   PubMed Web of Science ®Google Scholar
• Chou R, Qasseem A, Snow V, Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147:478-91
   PubMed Web of Science ®Google Scholar
• Airaksinen O, Brox J, Cedraschi C, European guidelines for the management of chronic nonspecifc low back pain. Eur Spine J 2006;15(Suppl 2):S192-300
   PubMed Web of Science ®Google Scholar
• Dworkin R, O'Connor A, Backonja M, Pharmacological management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51
   PubMed Web of Science ®Google Scholar
• Buckhardt C, Goldenberg D, Crofford L, Guideline for the management of fibromyalgia syndrome pain in adults and children. Guidelines 2005. Available from: http://www.guidelines.gov/content.aspx?id=14869. [Last accessed 26 January 2011]
   Google Scholar
• Carville S, Arendt-Nielsen S, Bliddal H, EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41
   PubMed Web of Science ®Google Scholar
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2005;43:879-923
   Google Scholar
• Lee C, McTavish D, Sorkin E. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993;46:313-40
   PubMed Web of Science ®Google Scholar
• Mattia C, Coluzzi F. Once-daily tramadol in rheumatological pain. Expert Opin Pharmacother 2006;7:1811-23
   PubMed Web of Science ®Google Scholar
• Mongin G, Yakusevich V, Kope A, Efficacy and safety assessment of a novel once-daily tablet formulation of tramadol: a randomised, controlled study versus twice-daily tramadol in patients with osteoarthritis of the knee. Clin Drug Investig 2004;24:545-8
   PubMed Web of Science ®Google Scholar
• Adler L, McDonald C, O'Brien C, Wilson M. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol 2002;29:2196-9
   PubMed Web of Science ®Google Scholar
• Bodalia B, McDonald C, Smith K, A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage 2003;25:142-9
   PubMed Web of Science ®Google Scholar
• Beaulieu A, Peloso P, Bensen W, A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain. Clin Ther 2007;29:49-60
   PubMed Web of Science ®Google Scholar
• Raffa R, Friderichs E, Reimann W, Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993;267:331-40
   PubMed Web of Science ®Google Scholar
• Raffa R, Pergolizzi J, Tallarida R. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain 2010;11:701-9
   PubMed Web of Science ®Google Scholar
• Ide S, Minami M, Ishihara K, Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacol 2006;51:651-8
   PubMed Web of Science ®Google Scholar
• Raffa R, Friderichs E, Reimann W, Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992;260:275-84
   PubMed Web of Science ®Google Scholar
• Friderichs E, Reimann W, Selve N. Contribution of both enantiomers to antinociception of the centrally acting analgesic tramadol. Naunyn Schmiedebergs Arch Pharmacol 1992;346(Suppl 1):R36
   Google Scholar
• Gillen C, Haurand M, Kobelt D, Wendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:116-21
   PubMed Web of Science ®Google Scholar
• Wu W, McKown L, Liao S. Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 2002;32:411-25
   PubMed Web of Science ®Google Scholar
• Hennies H-H, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneim Forsch 1988;38:877-80
   PubMed Web of Science ®Google Scholar
• Lai J, Ma S-W, Porreca F, Raffa R. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 1996;316:369-72
   PubMed Web of Science ®Google Scholar
• Codd E, Shank R, Schupsky J, Raffa R. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274:1263-70
   PubMed Web of Science ®Google Scholar
• Driessen B, Reimann W. Effects of tramadol on noradrenaline release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol 1989;339(Suppl):R89
   Google Scholar
• Friderichs E, Reimann W, Selve N. Investigations on opioid and non-opioid components in tramadol antinociception. Naunyn Schmiedebergs Arch Pharmacol 1991;344(Suppl 1):R72
   Google Scholar
• Driessen B, Reimann W. Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol 1992;105:147-51
   PubMed Web of Science ®Google Scholar
• Kayser V, Besson J-M, Guilbaud G. Evidence for a noradrenergic component in the antinociceptive effect of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat. Eur J Pharmacol 1992;224:83-8
   PubMed Web of Science ®Google Scholar
• Sora I, Takahashi N, Funada M, Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997;94:1544-9
   PubMed Web of Science ®Google Scholar
• Collart L, Luthy C, Dayer P. Multimodal analgesic effect of tramadol. Annual meeting of the American Society of Clinical Pharmacology and Therapeutics, Honolulu, March 1993. Clin Pharmacol Ther 1993;53:223
   Google Scholar
• Yanarates O, Dogrul A, Yildirim V, Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways. Anesthesiology 2010;112:696-710
   PubMed Web of Science ®Google Scholar
• Desmeules J, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996;41:7-12
   PubMed Web of Science ®Google Scholar
• Christoph T, Kogel B, Strassburger W, Schug S. Tramadol has a better potency ratio relative to morphine in neuropathic than in nociceptive pain models. Drugs R D 2007;8:51-7
   PubMedGoogle Scholar
• Stamer U, Musshoff F, Kobilay M, Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007;82:41-7
   PubMed Web of Science ®Google Scholar
• Stamer U, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008;107:926-9
   PubMed Web of Science ®Google Scholar
• Kleine-Brueggeney M, Musshoff F, Stuber F, Stamer U. Pharmacogenetics in palliative care. Forensic Sci Intern 2010;203:63-70
   PubMedGoogle Scholar
• Johansson I, Ingelman-Sundberg M. Genetic polymorphisms and toxicology – with emphasis on cytochrome P450. Toxicol Sci Advance 2010;120(1):1-13
   PubMedGoogle Scholar
• Kim E, Choi C-B, Kang C, Bae S-C. Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants. Ann Rheum Dis 2010;69:1889-90
   PubMedGoogle Scholar
• Roth S. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998;25:1358-63
   PubMed Web of Science ®Google Scholar
• Bird H, Hill J, Stratford M, A double-blind cross-over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. J Drug Dev Clin Pract 1995;7:181-8
   Google Scholar
• Jensen E, Ginsberg F. Tramadol versus dextropropoxyphene in the treatment of osteoarthritis. A short term double-blind study. Drug Invest 1994;8:211-18
   Web of Science ®Google Scholar
• Katz W. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs 1996;52(Suppl 3):39-47
   PubMedGoogle Scholar
• Schnitzer T, Kamin M, Olson W. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Athritis Rheum 1999;42:1370-7
   PubMed Web of Science ®Google Scholar
• Wilder-Smith C, Schimke J, Osterwalder B, Senn H-J. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994;5:141-6
   PubMed Web of Science ®Google Scholar
• Russell I, Kamin M, Bennett R, Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Gray W, Paster R, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000;27:772-8
   PubMed Web of Science ®Google Scholar
• Hair P, Curran M, Keam S. Tramadol extended-release tablets in moderate to moderately severe chronic pain in adults: profile report. CNS Drugs 2007;21:259-63
   PubMedGoogle Scholar
• Contramid. Labopharm 2011. Available from: http://www.labopharm.com/default.aspx?id=31. [Last accessed 26 January 2011]
   Google Scholar
• CIP Tramadol ER. 2011. Available from:http://www.cipherpharma.com/products/cip-tramadol-er/. [Last accessed 26 January 2011]
   Google Scholar
• Rosenberg M. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009;53:1531-43
   Google Scholar
• Smith B, Torrance N, Bennett M, Lee A. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007;23:143-9
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Lanteri-Minet M, Attal N, Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-7
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Haanpaa M, EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69
   PubMed Web of Science ®Google Scholar
• Ho T, Backonja M, Ma J, Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain 2009;141:19-24
   PubMedGoogle Scholar
• Jensen T, Madsen C, Finnerup N. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 2009;22:467-74
   PubMed Web of Science ®Google Scholar
• Dworkin R, O'Connor A, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(Suppl):S3-14
   Google Scholar
• Sindrup S, Madsen C, Brosen K, Jensen T. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999;66:636-41
   PubMed Web of Science ®Google Scholar
• Harati Y, Gooch C, Swenson M, Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-6
   PubMed Web of Science ®Google Scholar
• Kroenke K, Krebs E, Bair M. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009;31:206-19
   PubMed Web of Science ®Google Scholar
• Marcus D. Fibromyalgia: diagnosis and treatment options. Gender Med 2009;6:139-51
   PubMedGoogle Scholar
• Attal N, Mazaltarine G, Perrouin-Verbe B, Albert T. Chronic neuropathic pain management in spinal cord injury patients. What is the efficacy of pharmacological treatments with a general mode of administration? (Oral, transdermal, intravenous). Ann Phys Rehab Med 2009;52:124-41
   PubMedGoogle Scholar
• Wilder-Smith C, Hill L, Laurent S. Postamputation pain and sensory changes in treatment-naive patients: characteristics and responses to treatment with tramadol, amitriptyline, and placebo. Anesthesiology 2005;103:619-28
   PubMedGoogle Scholar
• Sindrup S, Andersen G, Madsen C, Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999;83:85-90
   PubMed Web of Science ®Google Scholar
• Kraychete D, Sakata R, Issy A, Proinflammatory cytokines in patients with neuropathic pain treated with tramadol. Rev Bras Anestesiol 2009;59:297-303
   PubMedGoogle Scholar
• Cepeda M, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and meta-analysis. J Rheumatol 2007;34:543-55
   PubMed Web of Science ®Google Scholar
• Babul N, Noveck R, Chipman H, Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
   PubMed Web of Science ®Google Scholar
• Gana T, Pascual M, Fleming R, Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22:1391-401
   PubMed Web of Science ®Google Scholar
• Vorsanger G, Xiang J, Jordan D, Farrell J. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clin Ther 2007;29:2520-35
   PubMedGoogle Scholar
• Malonne H, Coffiner M, Sonet B, Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1774-82
   PubMed Web of Science ®Google Scholar
• Fishman R, Kistler C, Ellerbusch M, Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). J Opioid Manag 2007;3:273-80
   PubMedGoogle Scholar
• Burch F, Fishman R, Messina N, A comparison of the analgesic efficacy of tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. J Pain Symptom Manage 2007;34:328-38
   PubMed Web of Science ®Google Scholar
• Kean W, Bouchard S, Roderich-Gossen E. Women with pain due to osteoarthritis: the efficacy and safety of a once-daily formulation of tramadol. Pain Med 2009;10:1001-11
   PubMedGoogle Scholar
• Beaulieu A, Peloso P, Haraoui B, Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manage 2008;13:103-10
   PubMed Web of Science ®Google Scholar
• Karlsson M, Berggren A-C. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther 2009;31:503-13
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDs: a randomized study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001;91:3-31
   Google Scholar
• Leppert W, Majkowicz M. The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain. Int J Clin Pract 2010;64:1681-7
   PubMed Web of Science ®Google Scholar
• Langley P, Patkar A, Boswell K, Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin 2010;26:239-51
   PubMed Web of Science ®Google Scholar
• Thorne C, Beaulieu A, Callaghan D, A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. Pain Res Manage 2008;13:93-102
   PubMed Web of Science ®Google Scholar
• Wilder-Smith C, Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol 1997;43:71-5
   PubMedGoogle Scholar
• Murphy D, Sutton A, Prescott L, Murphy M. A comparison of the effects of tramadol and morphine on gastric emptying in man. Anaesthesia 1997;52:1224-9
   PubMedGoogle Scholar
• Staritz M, Poralla T, Manns M, Buschenfelde K. Effect of modern analgesic drugs (Tramadol, pentazocine, and buprenorphine) on the bile duct sphincter in man. Gut 1986;27:567-9
   PubMed Web of Science ®Google Scholar
• Hair P, Curran M, Keam S. Tramadol extended-release tablets. Drugs 2006;66:2017-27
   PubMed Web of Science ®Google Scholar
• Teppema L, Nieuwenhuijs D, Olievier C, Dahan A. Respiratory depression by tramadol in the cat: involvement of opioid receptors. Anesthesiology 2003;98:420-7
   PubMed Web of Science ®Google Scholar
• Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep 2009;61:978-92
   PubMed Web of Science ®Google Scholar
• Pascual M, Fleming R, Gana T, Vorsanger G. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Curr Med Res Opin 2007;23:2531-42
   PubMed Web of Science ®Google Scholar
• Malonne H, Coffiner M, Fontaine D, Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther 2005;30:113-20
   PubMed Web of Science ®Google Scholar
• ULTRAM ER (tramadol HCl) extended-release tablets. US prescribing information 2006. Available from: http://www.ortho-mcneil.com/ortho-mcneil/shared/pi/ultramer.pdf. [Last accessed 15 January 2010]
   Google Scholar
• Morin C, Gibson D, Wade J. Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain 1998;14:311-14
   PubMed Web of Science ®Google Scholar
• Kosinski M, Janagap C, Gajria K, Pain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritis. Curr Med Res Opin 2007;23:1615-26
   PubMed Web of Science ®Google Scholar
• Florete O, Xiang J, Vorsanger G. Effects of extended-release tramadol on pain-related sleep parameters in patients with osteoarthritis. Expert Opin Pharmacother 2008;9:1817-27
   PubMed Web of Science ®Google Scholar